Test Name
PDL1, IMMUNOHISTOCHEMISTRY
Aliases
-
Abbreviations
PDL1 IHC; PD-L1 IHC
Test Classification
INDIVIDUAL
Department
ANATOMIC PATHOLOGY
Sub Department
HISTOLOGY
TAT Category
ELAPSED (CONTINUOUS) TIME
Estimated TAT
14
TAT Units
DAYS
Test Requirements
Formalin fixed, paraffin embedded blocks. Residual tissue with tumor must be available on the block.
Transport at room temperature (20-25 degrees C); protect from excessive heat.
Clinical history and original H&E report are mandatory. PD-L1 IHC shall ONLY be performed when a confirmed histopathologic diagnosis and intended immunotherapy context are documented, ensuring correct clone selection, scoring methodology, and clinically valid interpretation.
PD-L1 IMMUNOHISTOCHEMISTRY ORDER MUST NOT BE REGISTERED BEFORE VERIFYING TUMOR TYPE (E.G. NSCLC, HNSCC, GASTRIC ADENOCARCINOMA, UROTHELIAL CARCINOMA, TNBC) AND THERAPEUTIC INTENT (SPECIFIC TARGETED TREATMENT AGENT E.G. PEMBROLUZIMAB, NIVOLUMAB ETC.
Clinical Utility
Theranostic / predictive for response to PDL1 targeted therapy e.g. Pembroluzimab (Keytruda), Nivolumab, Durvalumab, Atezolizumab, Avelumab.
PDL1 ordering is not a one size fits all situation; selection of the right PDL1 IHC clone is dependent on:
1) The exact histopathologic diagnosis
2) The specific targeted drug therapy e.g. Pembroluzimab (Keytruda)? Atezolizumab? Nivolumab? etc.
Last Review
26th Feb 2026